References
1 Shao, C. et al. Risk factors associated with COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease during the SARS-CoV-2 pandemic. J Med Virol 95 , e29098, doi:10.1002/jmv.29098 (2023).
2 Gunay, S. et al. Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up.Sarcoidosis Vasc Diffuse Lung Dis 40 , e2023029, doi:10.36141/svdld.v40i3.14418 (2023).
3 DeDent, A. M. & Farrand, E. Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccination. Thorax77 , 9-10, doi:10.1136/thoraxjnl-2021-217985 (2022).
4 Mackintosh, J. A., Wells, A. U., Cottin, V., Nicholson, A. G. & Renzoni, E. A. Interstitial pneumonia with autoimmune features: challenges and controversies. Eur Respir Rev 30 , doi:10.1183/16000617.0177-2021 (2021).
5 WHO – COVID19 Vaccine Tracker. https://covid19.trackvaccines.org/agency/who/. Accessed 17 Dep 2023.
6 Amiya, S. et al. Case report: Acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination.Int J Infect Dis 116 , 255-257, doi:10.1016/j.ijid.2022.01.031 (2022).
7 Sattui, S. E. et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 7 , doi:10.1136/rmdopen-2021-001814 (2021).
8 Liossis, S. C. & Bounia, C. A. Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion. Front Med (Lausanne) 9 , 937561, doi:10.3389/fmed.2022.937561 (2022).
9 Peng, K. et al. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study. EClinicalMedicine 63 , 102154, doi:10.1016/j.eclinm.2023.102154 (2023).
10 Valenzuela, C., Waterer, G. & Raghu, G. Interstitial lung disease before and after COVID-19: a double threat? Eur Respir J58 , doi:10.1183/13993003.01956-2021 (2021).